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Abstract
Background: A number of components in soy appear to have anticancer properties, including the
isoflavones, genistein and daidzein. The use of soy by women with breast cancer is now being
questioned because of the estrogen-like effects of isoflavones and possible interactions with
tamoxifen. Clinicians providing nutrition counseling to these women are concerned because the
availability of soy foods has increased dramatically in the past few years. The goal of this study was
to quantify the intake of isoflavones in women with breast cancer.
Methods: A cross-sectional study of 100 women with breast cancer treated at Cancer Treatment
Centers of America® between 09/03 and 02/04. Each patient completed a soy food frequency
questionnaire (FFQ) that was scored by Fred Hutchinson Cancer Research Center. Demographic
and clinical predictors of soy intake were evaluated using one-way non-parametric Mann Whitney
test and non-parametric spearman's rank correlation.
Results: Mean age was 50.5 years (std. dev. = 9.4; range 31–70) and mean BMI was 27.3 kg/m2 (std.
dev. = 6.75; range 17–59). Genistein and Daidzein consumption was limited to 65 patients with a
mean intake of 11.6 mg/day (std. dev. = 21.9; range 0–97.4) and 7.6 mg/day (std. dev. = 14.1; range
0–68.9) respectively. Soy milk (37%) and pills containing soy, isoflavones, or "natural" estrogen
(24%) were the two biggest contributors to isoflavone intake.
Conclusion: Our study suggests that the isoflavone intake of breast cancer patients at our hospital
was quite variable. Thirty-five patients reported no soy intake. The mean daily intake of 11.6 mg
genistein and 7.4 mg daidzein, is the equivalent of less than 1/4 cup of tofu per day. This amount is
higher than what has been previously reported in non-Asian American women.
Background
Soy foods are known to have a number of health benefits,
ranging from the well-documented cholesterol-lowering
effects of soy protein, which may lower risk of cardiovas-
cular disease [1], to the potential for decreasing bone loss
in healthy, postmenopausal women [2,3]. A number of
soy components are also thought to have anticancer prop-
erties, including isoflavones (genistein, daidzein, gly-
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citein), phytic acid, protease inhibitors, saponins,
phytosterols and lignans [4]. Indeed, in vitro research
indicates that isoflavones in particular may have antiestro-
genic effects [5] and rodent studies have demonstrated
associations of decreased risk of mammary tumors with
soy intake [6]. Furthermore, it has been suggested that the
lower risk for developing breast cancer in Asian countries
may be related to soy intake [7-9]. A meta-analysis by
Trock, et. al found that soy intake was associated with a
14% reduced risk of breast cancer in all women [10].
However, amid this promising research, other studies
have raised the question of potential risk associated with
the consumption of soy by women with breast cancer due
to possible estrogenic effects of soy. An animal study in
ovariectomized mice by Hsieh et al. using MCF-7 estrogen
receptor (ER) positive breast cancer cells showed that low
(and physiologically significant) concentrations of genis-
tein may stimulate the proliferation of these cells [11].
Another study, in ovariectomized, athymic mice
implanted with MCF-7 cells, found that genistein negated
the inhibitory effect of tamoxifen on MCF-7 tumor growth
in vivo [12]. One of the few human studies available
noted epithelial cell hyperplasia as well as increased nip-
ple-fluid aspirate in post-menopausal women who con-
sumed an isoflavone-rich diet [13]. Because no clear
consensus about the physiological effects of soy exists, the
consumption of soy foods by women with breast cancer
has become a controversial issue, and the need for further
research continues to exist.
Meanwhile, clinicians providing counseling to breast can-
cer patients are concerned because the availability, famil-
iarity and therefore, consumption, of soy foods by the
American public has increased dramatically over the past
15 years [14,15]. Numerous studies have examined the
soy food intake of Asian women [16,17], Dutch women
[18], US women [19] and even women at high risk for
breast cancer [20], however, very limited information is
available regarding the consumption of soy foods by
women actually diagnosed with breast cancer. This study
attempts to quantify the amount and type of soy food
intake in women with breast cancer.
Methods
Study Population
This cross-sectional study investigated a consecutive case
series of 100 new breast cancer patients treated at Cancer
Treatment Centers of America® (CTCA) at Midwestern
Regional Medical Center (MRMC) between 09/03 and 02/
04. Only patients with a histologically confirmed diagno-
sis of breast cancer were included in this study. Other cri-
teria for entry into the study included a minimum age of
18 years, willingness to sign informed consent and literacy
in the English language. Patients were excluded if they
were unable to give informed consent or understand or
cooperate with study conditions. Every new patient with a
diagnosis of breast cancer that scheduled an appointment
at our institution between 09/03 and 02/04 was asked to
participate in this study. One hundred percent of patients
consented to participate, often citing a willingness to help
others with this disease, as their primary motivator.
A trained registered dietitian described the study and
determined eligibility after patients signed in at the clinic.
As part of the consent process, patients were assured that
refusal to participate in the study would not affect their
future care in any way. Patients filled in the questionnaires
before undergoing any therapy at our hospital. The Insti-
tutional Review Board at MRMC approved the study.
Questionnaire
After obtaining informed consent, each patient was asked
to complete a soy food frequency questionnaire (FFQ)
that was developed and validated by Fred Hutchinson
Cancer Research Center. A detailed description of the FFQ
has been previously published, but briefly, this 40-item
soy FFQ was developed specifically to estimate soy food
consumption and isoflavone intake over the past 3
months. For each food item, respondents were asked
about frequency of consumption and the usual serving
size consumed for each food. Options for portions size
were small, medium, or large. Examples were given for a
medium portion of each food item. A small portion was
defined as a half of a medium portion and a large portion
as one and a half times that of a medium portion. Isofla-
vone calculations were performed using the Nutrient Data
System for Research (NDS-R) software version developed
by the Nutrition Coordinating Center, University of Min-
nesota, Minneapolis, MN, Food and Nutrition Database.
This FFQ was found to be reliable in two different studies
examining two different populations [21,22]. Isoflavone
values from this FFQ have also been shown to correlate
well with blood levels of isoflavones [23]. In addition to
completing the FFQ, subjects were also asked to detail any
changes they had made to their diets since being diag-
nosed with cancer by answering two additional questions.
The first question asked, "which response best describes
your current diet?" The choices for this question included:
Standard American diet, lacto-ovo vegetarian, no red
meat, vegan, macrobiotic, & other with a blank for fill-in.
The second question was open-ended & simply asked if
any changes had been made to diet post-diagnosis. If the
answer was yes, a description was requested. These
responses were then categorized and coded for analysis.
Statistical Analysis
All data were analyzed using SPSS 11.5 (SPSS Inc., Chi-
cago, IL, USA). Means, medians and standard deviations
of genistein and daidzein intake were calculated. SoyNutrition Journal 2009, 8:2 http://www.nutritionj.com/content/8/1/2
Page 3 of 7
(page number not for citation purposes)
foods with highest reported consumption were deter-
mined. All continuous variables were examined for nor-
mal distribution. Demographic and clinical predictors of
soy intake (genistein and daidzein intake) were evaluated
using one-way non-parametric Mann Whitney test or
non-parametric spearman's rank correlation depending
upon the underlying distributions of the variables.
Among the predictors to be evaluated were age at diagno-
sis, body mass index (BMI), stage at diagnosis, ethnicity,
prior treatment history (newly diagnosed versus those
who had failed prior treatment elsewhere), menstrual sta-
tus, estrogen and progesterone receptor status, and
tamoxifen use. The soy consumption was categorized into
2 groups: those who had consumed any soy food in the
last three months versus those who had not. The relation-
ship of demographic and clinical predictors was also
examined with the following soy consumption variables:
weekly gram weight of soy foods consumed, weekly milli-
grams of genistein in soy foods consumed and weekly
milligrams of daidzein in soy foods consumed. The signif-




A total of 100 breast cancer patients were approached in
the clinic between 9/03 and 2/04 and were screened for
eligibility by the clinical oncology nutritionist. One Hun-
dred patients were found to be eligible for participation.
Of 100 eligible patients, 100 consented to participate and
completed the soy survey. The final study sample con-
sisted of 100 patients with a response rate of 100%. The
majority of this cohort was white (81%). The mean age
was 50.5 years (std. dev. = 9.4; range 31–70). The mean
BMI was 27.3 (std. dev. = 6.7; range 17.1–59.2). Fifty-nine
percent were ER+, 37% ER-, and 4% unknown. Twenty-
nine percent were on tamoxifen, 7% on Arimidex, % 11%
on both. Twenty-three percent of participants reported
following a vegetarian diet. Table 1 describes the charac-
teristics of our patient cohort in greater detail.
Prevalence of Soy Use
The prevalence of soy consumption in our patient cohort
was 65%. Consumers were defined as those who con-
sumed at least one soy food in the past three months. The
mean intake of genistein and daidzein in the previous
three months was 11.6 mg/day (std. dev. = 21.9; range 0–
97.4) and 7.6 mg/day (std. dev. = 14.1; range 0–68.9)
Table 1: Subject characteristics (N = 100)
Characteristic Categories Number Percent (%)
Ethnicity Caucasian 81 81
African American 15 15
Hispanic 3 3
Asian 1 1
Tumor Stage at Diagnosis Stage 0 4 4
Stage I 21 21
Stage II 44 44
Stage III 17 17
Stage IV 11 11
Unknown 3 3




ER/PR status ER + PR + 48 48
ER + PR - 11 11
ER - PR + 1 1
ER - PR - 36 36
Unknown 4 4
Tamoxifen/Arimidex use Neither 50 50
Tamoxifen only 29 29
Arimidex only 7 7
Both 11 11
Unknown 3 3Nutrition Journal 2009, 8:2 http://www.nutritionj.com/content/8/1/2
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respectively. Median intake of genistein and daidzein was
1 mg/day and 0.64 mg/day respectively. Table 2 provides
data on the soy foods with the highest reported consump-
tion. Table 3 provides data on the major contributors to
isoflavone intake.
Predictors of Soy Use
Age at diagnosis, BMI, and weekly milligrams intake of
genistein and daidzein were non-normally distributed
and therefore non-parametric methods were used to ana-
lyze the relationships between them. Table 4 displays the
results of Spearman Rank correlation analyses between
the demographic and clinical factors and soy consump-
tion. The results for weekly consumption of genistein and
daidzein in milligrams were very similar to each other.
Ethnicity and Tamoxifen use were weakly (but signifi-
cantly) correlated with soy consumption. Forty-eight out
of 81 Caucasians (59.3%) consumed soy whereas 15 out
of 15 African-Americans (100%) consumed soy. Sixteen
out of 29 (55.2%) patients with Tamoxifen use consumed
soy whereas 5 out of 7 patients with Arimidex use (71.4%)
consumed soy. Stage at diagnosis was significantly corre-
lated with the three continuous soy consumption varia-
bles. The mean daily milligram of genistein consumed
was 5.0, 10.8, 10.0, 0.77, and 5.1 in stages 0, I, II, III and
IV respectively. The mean daily milligram of diadzein con-
sumed was 3.2, 7.2, 6.4, 0.53, and 3.4 in stages 0, I, II, III
and IV respectively. Thus, stages I and II had the highest
consumption of genistein and diadzein while stage III had
the lowest consumption.
An interesting relationship was observed between the
change in diet after cancer diagnosis question and soy
intake. The mean daily milligram of genistein consumed
was 5.6 and 10.8 respectively for those who did not
change their diet after cancer diagnosis (n = 30) and those
who switched over to a more vegetarian diet (n = 23). Sim-
ilarly, the mean daily milligram of diadzein consumed
was 3.3 and 7.0 for those who did not change their diet
after cancer diagnosis (n = 30) and those who switched
over to a more vegetarian diet (n = 23). In the open ended
question asking respondents to describe changes to their
diets since diagnosis, 14 respondents mentioned soy
intake. Interestingly, there were 7 responses reporting
increasing soy intake since diagnosis, and 7 responses
reporting decreasing soy intake since diagnosis. In addi-
tion to changing towards a vegetarian diet, other changes
mentioned were decreasing sugar, increasing vegetables
and fruits, decreasing portions, & decreasing fat.
Discussion
In our study of 100 women diagnosed with breast cancer,
the intake of soy isoflavones was quite variable ranging
from 0 to 161.4 mg per day. This is similar to the range of
0 to > 150 mg/day reported by Frankenfeld et al. [23]. We
found 35% of these subjects to be soy non-consumers,
which is also similar to the findings by Frankenfeld et al.
[22,23].
The mean intake of isoflavones in this population is
higher than that reported in other US women and in
women in the Bay Area Breast Cancer Study [19,24], but
lower than that reported in Asian populations [25-27].
Isoflavone intake in the women in this study was similar
to that previously reported for vegetarians [21,22]. In fact,
many of the patients in this study reported making diet
changes since their diagnosis. Twenty-three patients
reported following a vegetarian diet.
The ten soy foods with the highest reported consumption
(Table 2) contributed to 68% of isoflavone intake. Soy
sauce and soy condiments had the highest reported con-
sumption, yet contributed very little to isoflavone intake
(see Table 3). Soymilk and pills containing soy, isofla-
vones, or "natural" estrogens contributed to 61% of total
isoflavone (daidzen and genistein) intake of all partici-
pants (Table 3). An interesting finding was that these pills
contributed to 24% of total isoflavone intake of all partic-
ipants, yet these pills were consumed by < 9% of the par-
ticipants. These pills can be very concentrated sources of
isoflavones. Women consuming these pills had isoflavone
intakes at the higher end of the range reported for this
cohort. These women had intakes of isoflavones that
exceeded 100 mg/day, which according to Messina and
Wood is an intake that no more than 5% of older adults
in Japan and China consume [27]. This suggests that some
Table 2: Ten soy foods with highest reported consumption




Roasted soy nuts 13
Tofu 13
Veggie soy or tofu burger 12
Soy cheese 12
Packaged mixed dishes with soy or tofu 10
Tofu or soy breakfast sausage 9
Soy drinks 9Nutrition Journal 2009, 8:2 http://www.nutritionj.com/content/8/1/2
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women with breast cancer may be consuming isoflavones
in amounts above and beyond what appears to be safely
consumed in Asian countries. Inquiring about isoflavone
supplement intake may be one way to screen women with
breast cancer for isoflavone consumption that may be
excessive.
Another interesting finding was that many of the foods
with high consumption were processed soy foods, includ-
ing bars, burgers, cheese, packaged dishes, sausages, and
drinks. In contrast, the soy consumed in Asian countries is
minimally processed. A study by Allred et al. evaluated
mice transplanted with MCF-7 cells that were exposed to
various soy products with equal amounts of genistein
aglycone equivalents. They found mice exposed to more
processed soy had increased tumor growth compared to
mice that received less processed soy [28]. This raises the
question of whether or not we should also be concerned
with the degree of processing in soy foods that are con-
Table 3: Top ten contributors to isoflavone intake
Soy Food Percent Contribution
Soymilk 37%
Pills containing soy, isoflavones, or "natural estrogens" 24%
Protein/energy bars containing soy 12%
Tofu 7%
Soy nuts 5%
Soy meat substitutes (e.g. burgers, TVP) 4%
Liquid nutrition drinks containing soy protein such as Odwalla Future Shake, Ensure Plus 3%
Soy protein powders 3%
Soy yogurt 3%
Miso soup 1%
Table 4: Spearman rank correlations between demographic and clinical factors and soy consumption (N = 100)
Predictors Soy consumption 
(yes versus no)
Weekly gram weight of 
soy
Weekly milligrams of 
Genistein
Weekly milligrams of 
Daidzein
Age at Diagnosis 0.014 0.06 0.12 0.12
BMI -0.04 -0.11 -0.11 -0.11
Ethnicity -0.23* 0.18 0.13 0.13
Stage at Diagnosis -0.18 -0.25* -0.25* -0.24*
Prior Treatment History -0.12 -0.19 -0.18 -0.18
Menstrual Status 0.07 0.11 0.14 0.14
Estrogen/Progesterone 
Receptor Status
0.16 0.08 0.07 0.07
Tamoxifen Use -0.21* -0.20 -0.16 -0.16
* p < 0.05Nutrition Journal 2009, 8:2 http://www.nutritionj.com/content/8/1/2
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sumed by women with breast cancer. Much research still
needs to be done in this area.
Several limitations of this study must be acknowledged.
The patient cohort was limited to only those patients who
were English-speakers and consisted largely of Caucasians
with breast cancer. This study sample, therefore, is not
broadly representative of breast cancer patients in general.
Our hospital offers a wide range of integrative cancer treat-
ment options including nutritional, naturopathic, mind
body medicine and spiritual therapies in conjunction
with conventional cancer care. It seems likely that many
patients seeking care at our hospital have a particular
interest in pursuing complementary therapies and may
therefore have a higher prevalence of soy use than the
broader population of patients with breast cancer. In fact,
many of the patients in this study reported making diet
changes since their diagnosis. Our sample size might not
have been large enough to accommodate the number of
post hoc subgroup comparisons made within this study.
This study was not an attempt to scientifically evaluate the
impact of soy consumption on breast cancer but rather to
describe what proportion of people with breast cancer use
soy foods. The non-normal distribution of age at diagno-
sis, BMI, and weekly milligrams intake of genistein and
daidzein could be a result of relatively small sample size
of our study.
FFQs have been criticized for being too vague when it
comes to serving sizes. The definition of serving sizes is
often open to individual interpretation. The soy FFQ used
in our study defines a medium serving size for the foods
in the questionnaire; and defines small and large servings
in relation to the medium serving. FFQs have also been
criticized for being prone to measurement error. How
often one consumes a particular food is often hard to
answer and/or remember. FFQs may result in underre-
porting based on the theory that people behave differently
when observed. Finally, the number of foods on a FFQ
can be limited, and preparation is not always taken into
account [29]. For example, the FFQ used in this study only
asked about soy foods. There are isoflavones in other
foods such as beans, peas, flour, coffee, etc., which were
not evaluated with this instrument. To this point, it has
been reported that isoflavone containing foods other than
soy make a minimal contribution to total isoflavone
exposure [19]. A possible defense of this limitation is that
we used a FFQ that has been validated when compared to
plasma levels of isoflavones and when given at different
intervals with time between measurements [21-23].
Conclusion
Despite these limitations, this study adds to the limited
information that currently exists on quantifying soy iso-
flavone intake in women with breast cancer. We found
isoflavone intake in women with breast cancer in this
study to be similar to the intake of isoflavones in vegetar-
ians, but less than that in Asian woman. Although vegetar-
ian diets can vary, they generally are not associated with
an increase in breast cancer risk or mortality [30,31].
Potential utility of this study is that clinicians may be able
to use the list of foods in Table 3 to quickly screen women
with breast cancer for isoflavone intake. As was previously
mentioned, asking women with breast cancer about iso-
flavone containing pills is one way to identify some
women with intakes that may be excessive. In this cohort,
soymilk, pills, and bars containing soy contributed to
73% of isoflavone intake. Asking about these three foods
may be one way to quickly estimate isoflavone intake in
women with breast cancer. Ideally, future studies should
evaluate isoflavone intake in women with breast cancer
being treated at multiple centers, in order to determine if
these results are broadly representative of isoflavone
intake in these women. Additional studies are also needed
to determine what a safe and acceptable level of isofla-
vone intake is in women with breast cancer given the
potential biphasic effect of isoflavone exposure.
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